Physician profile
Ryan R Turner
NPI 1780613109
$2,146.13
in general payments reported to CMS, 2019-2025
27 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $477 · 2021: $217 · 2022: $410 · 2023: $340 · 2024: $303 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $325.24 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $297.91 | 2019-2025 | Breztri |
| Lilly USA, LLC | $219.01 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $209.60 | 2019-2025 | |
| Novo Nordisk INC | $158.85 | 2022-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $129.36 | 2019-2022 | |
| Medtronic, INC. | $114.01 | 2022-2024 | Intellis Adaptivestim |
| Abbvie INC. | $105.76 | 2021-2024 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $66.17 | 2019-2022 | |
| Amgen INC. | $64.36 | 2019-2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.46 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $49.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $42.93 | 2019-2022 | |
| Dexcom, INC. | $38.49 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.39 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.32 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $30.77 | 2020-2023 | |
| Azurity Pharmaceuticals, INC. | $22.75 | 2024 | |
| Inspire Medical Systems, INC. | $20.73 | 2023 | Inspire |
| Allergan, INC. | $19.21 | 2020 | |
| Esperion Therapeutics, INC. | $17.98 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2023 | Nuedexta |
| Idorsia Pharmaceuticals US INC | $14.75 | 2023 | Quviviq |
| Abbott Laboratories | $14.69 | 2024 | Freestyle Libre 3 |
| Alcon Vision LLC | $14.43 | 2023 | Hydrus Microstent |
| Axsome Therapeutics, INC. | $13.90 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.